PlainPill

MK-677 vs Tirzepatide for appetite

Short answer: For appetite, more users report improvement with Tirzepatide — 84% of 79 reports, versus 66% of 228 for MK-677.

MK-677 has 0 meta-analyses and 15 randomized trials on PubMed; Tirzepatide has 214 and 132.

Based on 978 reports about MK-677 and 428 about Tirzepatide. Not medical advice.

MK-677
Substance
Tirzepatide
Medication
Users say it helped39%helped479 reports · high confidence75%helped287 reports · high confidence
Verdict
Mixed
Mostly positive
ResearchBResearch: ModerateAResearch: Strong
Meta-analyses / RCTs0 / 15214 / 132
Mainly used for
Appetite
% reporting improvement
66% (228)84% (79)
Weight loss
% reporting improvement
53% (55)94% (206)
Sleep
% reporting improvement
79% (170)56% (9)
Recovery
% reporting improvement
99% (106)—
Performance
% reporting improvement
90% (87)83% (12)
Common side effectswater retention, fatigue, stomach issues, hungernausea, fatigue, anhedonia, constipation
Typical dose reported12.5 mg / before dinnerNot listed
MK-677
What a user said
“From my own experience (also have suffered from poor sleep), i experienced a noticeable increase in sleep quality even with a low dose.”
Full MK-677 profile →
Tirzepatide
Latest review conclusion

This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.

Pharmacol Res, 2021 ↗
What a user said
“Tirzepatide works so well! Do some research in the r/peptides subreddit and the r/tirzepatide subreddit. It's the most effective thing I've ever seen for appetite suppressant.”
Full Tirzepatide profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate